Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5713469 | 0.97 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713436 | 0.89 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713473 | 0.89 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713456 | 0.87 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL3049355 | 0.87 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713450 | 0.86 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713446 | 0.86 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713434 | 0.86 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713439 | 0.86 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BMEN1KMT2A | |
| SCHEMBL5713488 | 0.86 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450797-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | EP | claimed |
| US-6624163-B2 | P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and Attention Deficit Hyperactivity Disorder | HOFFMAN-LA ROCHE INC. | 2003-09-23 | — | — | US | claimed |
| US-20030134855-A1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-07-17 | — | — | US | claimed |
| EP-1450797-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | EP | disclosed |
| EP-1450797-A1 | BENZOTHIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-01 | — | — | EP | disclosed |
| US-6624163-B2 | P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and Attention Deficit Hyperactivity Disorder | HOFFMAN-LA ROCHE INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030134855-A1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003045386-A1 | BENZOTHIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134855-A1 | BENZOTHIAZOLE DERIVATIVES | ADORA1, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA1 1/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.